620 related articles for article (PubMed ID: 30505301)
1. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Jelinek T; Paiva B; Hajek R
Front Immunol; 2018; 9():2431. PubMed ID: 30505301
[TBL] [Abstract][Full Text] [Related]
2. Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
Lesokhin AM; Bal S; Badros AZ
Cancer Immunol Res; 2019 Aug; 7(8):1224-1229. PubMed ID: 31371317
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
4. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
5. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
[TBL] [Abstract][Full Text] [Related]
6. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma.
Oriol A
Expert Rev Hematol; 2020 May; 13(5):435-445. PubMed ID: 32182438
[No Abstract] [Full Text] [Related]
7. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.
Jelinek T; Hajek R
Oncoimmunology; 2016; 5(12):e1254856. PubMed ID: 28123899
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
16. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Schmidt EV
Semin Immunopathol; 2019 Jan; 41(1):21-30. PubMed ID: 30374524
[TBL] [Abstract][Full Text] [Related]
17. Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Oliva S; Troia R; D'Agostino M; Boccadoro M; Gay F
Front Immunol; 2018; 9():2749. PubMed ID: 30538704
[TBL] [Abstract][Full Text] [Related]
18. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
Front Immunol; 2018; 9():2204. PubMed ID: 30319648
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
